CERO
USDCERo Therapeutics Holdings Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.335
Kõrge
$0.095
Madal
$0.095
Maht
8.44M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
177.4K
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.29M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Maxim Group Downgrades CERo Therapeutics Hldgs to Hold
Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs from Buy to Hold.
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.